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Abstract
Background: Activated complement system is known to mediate neuroinflammation and neurodegeneration 
following exposure to hypoxic-ischemic insults. Therefore, inhibition of the complement activation cascade may 
represent a potential therapeutic strategy for the management of ischemic brain injury. Decay-accelerating factor (DAF, 
also known as CD55) inhibits complement activation by suppressing the function of C3/C5 convertases, thereby 
limiting local generation or deposition of C3a/C5a and membrane attack complex (MAC or C5b-9) production. The 
present study investigates the ability of DAF to protect primary cultured neuronal cells subjected to sodium cyanide 
(NaCN)-induced hypoxia from degeneration and apoptosis.
Methods: Cultured primary cortical neurons from embryonic Sprague-Dawley rats were assigned one of four groups: 
control, DAF treatment alone, hypoxic, or hypoxic treated with DAF. Hypoxic cultures were exposed to NaCN for 1 hour, 
rinsed, followed by 24 hour exposure to 200 ng/ml of recombinant human DAF in normal medium. Human DAF was 
used in the present study and it has been shown to effectively regulate complement activation in rats. Neuronal cell 
function, morphology and viability were investigated by measuring plateau depolarization potential, counting the 
number dendritic spines, and observing TUNEL and MTT assays. Complement C3, C3a, C3a receptor (R) production, 
C3a-C3aR interaction and MAC formation were assessed along with the generation of activated caspase-9, activated 
caspase-3, and activated Src.
Results: When compared to controls, hypoxic cells had fewer dendritic spines, reduced plateau depolarization 
accompanied by increased apoptotic activity and accumulation of MAC, as well as up-regulation of C3, C3a and C3aR, 
enhancement of C3a-C3aR engagement, and elevated caspase and Src activity. Treatment of hypoxic cells with 200 
ng/ml of recombinant human DAF resulted in attenuation of neuronal apoptosis and exerted significant protection 
against neuronal dendritic spine loss and plateau depolarization reduction. Furthermore, treatment with DAF resulted 
in decreased accumulation of C3a, MAC, C3a-C3aR interaction, caspase-9, activated caspase-3, and pTyr416-Src 
(activated Src) tyrosine kinase.
Conclusion: DAF was found to reduce neuronal cell death and apoptosis in NaCN induced hypoxia. This effect is 
attributed to the ability of DAF to limit complement activation and inhibit the activity of Src and caspases 9 and 3. This 
study supports the inhibiting of complement as a neuroprotective strategy against CNS ischemia/reperfusion injury.
Background
Neuroinflammation and degeneration occurs following
hypoxic-ischemic insults such as traumatic brain injury
( T B I )  o r  c h e m i c a l  e x p o s u r e  t o  n e u r o t o x i c  a g e n t s  [ 1 ] .
Neuroinflammation and degeneration often share com-
mon pathways frequently leading to neuronal cell death
[2]. Complement represents an important mediator dur-
ing the neurodegenerative process by releasing proin-
flammatory mediators and anaphylatoxins such as C3a
and C5a as well as producing MAC [3]. Complement
fragments and C3aR have been demonstrated in normal
and ischemic brain tissue [4]. Complement depletion has
been shown to reduce post-ischemic brain injury in rats
and mice [4]. It has been suggested that complement acti-
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vation levels in the central nervous system (CNS) follow-
ing brain injury might increase after blood brain barrier
(BBB) break-down [5,6] and might come from cellular
sources such as astrocytes, microglia, oligodendrocytes
and neurons in response to cerebral ischemia or brain
trauma [1,7,8]. In addition, astrocytes and microglia
express complement inhibitors on their membranes to
control complement activation and mitigate comple-
ment-mediated injury [9]. Neurons express low levels of
complement regulators compared to astrocytes and it has
been suggested that human fetal neurons have the capac-
ity to spontaneously activate the complement system
[10].
Inhibition of complement activation using biologics
such as soluble complement receptor type 1 (sCR1), C1
inhibitor (C1-INH), C3 convertase inhibitor (Crry), C5a
monoclonal antibodies, and C5a receptor antagonists
have been shown to reduce post TBI [4,11]. Complement
system can be activated via the classical pathway, such as
by IgG activation, or by the alternative pathway, such as
by factor B activation [12]. In a recent study, intravenous
immunoglobulin (IVIG) was demonstrated to protect the
brain against injury from experimental stroke in mice [4].
Therefore, targeting the complement cascade represents
a potential treatment strategy for the management of
ischemic brain injury.
Decay-accelerating factor (DAF, also known as CD55),
a ubiquitously expressed intrinsic complement regulatory
protein, inhibits complement activation by inhibiting the
function of C3/C5 convertases in both the classic and
alternative pathways thereby limiting local C3a/C5a and
MAC production [13]. Human NT2-N neurons constitu-
tively express DAF which is down-regulated after severe
hypoxia and subsequent reoxygenation with human
serum [14]. It has been previously shown that increased
expression of DAF plays an important role in the reduc-
tion of cerebral damage by steroids after Traumatic Brain
Injury [15]. It has been demonstrated that inhibition of
complement activation by human recombinant DAF
results in local and remote tissue protection during mes-
enteric ischemia/reperfusion in mice [16]. A common
model of chemical ischemia in cultured cells involves
exposure to cyanide [17]. In the present study, we evalu-
ated the effect of recombinant human DAF on cultured
embryonic rat primary neurons subjected to chemically
induced hypoxia. Harris et al. 2000 reported that neither
human nor rodent DAF are species restricted meaning
they can regulate both homologous and heterologous
complement activation, suggesting cross-reactivity
between human recombinant DAF in rodent prepara-
tions [18]. Results indicate that 200 ng/ml of DAF treat-
ment protects rat neurons from injury by suppressing the
complement cascade as well as by inhibiting the activa-
tion of caspase and Src tyrosine kinase.
Methods
Primary neuron culture and experimental groups
An established chemical hypoxia model was chosen that
mimics ischemia via chemical manipulation with NaCN
(17, 19). Sprague-Dawley rat cortex was dissected at
embryonic day 17, dissociated in Ca2+  and Mg2+-free
Hanks balanced salt solution containing 0.125% trypsin
for 20 min. Cells were plated and cultured in 10% FBS/
DMEM with humidified 5% CO2 incubator at 37°C over-
night then replaced the medium with serum-free neu-
robasal medium containing B27 supplement (Invitrogen,
MD). Those cells were treated with 3 μM cytosine arabi-
noside (Sigma) after DIV 3 for 24 h and replaced with
Neurobasal supplemented with B27 and maintained for
12 ~ 18 days. Approximately 90% of the cultured cells
were neurons, verified by neuronal marker neurofilament
200 (NF-200), the remaining cells labeled positive for
GFAP, indicating that they were astrocytes. Cultured pri-
mary cortical neurons (12-18 days) were assigned to of
four groups: 1) Control: cells incubated with normal basal
medium; 2) DAF Treatment Alone: cells treated with nor-
mal basal medium in the presence of 200 ng/ml of recom-
binant human DAF for 24 hours; 3) Hypoxia (NaCN):
cells exposed to 1.5 mM of NaCN for 1 hour in glucose-
free neurobasal medium [19], rinsed, then followed by
normal basal medium for 24 hours; 4) chemical Hypoxia
(NaCN) +DAF Treatment: cells exposed to 1.5 mM of
NaCN for 1 hour in glucose-free neurobasal medium,
rinsed, then followed by normal basal medium with 200
ng/ml of recombinant human DAF for 24 hours.
Complement expression and distribution
Antibodies and reagents
Recombinant human DAF was obtained from R&D sys-
tems (Minneapolis, MN). NaCN, CNQX, D-AP5, and
mouse anti-NF-200 antibody were from Sigma-Aldrich,
Inc. (St. Louis, MO). Chicken anti-mouse C3a and goat
anti-chicken IgY (H&L) antibodies were from Abcam Inc.
(Cambridge, MA). Mouse anti-rat MAC primary mono-
clonal an tibody was provided as a gift by Dr J. Pippin
(University of Washington). Mouse anti-human C3, and
goat anti-mouse DAF antibodies were purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Mouse
anti-rat C3aR antibody was from Cell Sciences (Canton,
MA). Anti-Caspase 9, Anti-cleaved Caspase 3 (activated
Caspase 3) and anti-Tyr416-Src antibodies (activated Src)
were purchased from Cell Signaling (Danvers, MA). Goat
anti-mouse Alexa Fluor 488-, goat anti-rabbit 594-conju-
gated secondary antibodies, and ProLong Gold antifade
reagent were from Invitrogen (Carlsbad, CA).
Western blotting
Cells (2 × 106) were lysed in RIPA buffer. The Cell lysates
were separated on SDS gel according to the manufac-
turer's protocols (Invitrogen Corp.). The proteins wereWang et al. Journal of Neuroinflammation 2010, 7:24
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then transferred onto PVDF and blotted with various
antibodies as indicated in the figures. Protein bands were
detected by chemiluminescence reagents (Amersham
Biosciences).
Immunofluorescent staining
Cells were seeded on a poly-D-lysine coated cover slip of
12 mm diameter at a density of 1 × 105 in 24-well plate.
After chemical hypoxia, cells were fixed with 4% para-
formaldehyde for 30 min, permeabilized with 0.1% Triton
X-100 for 10 min, and blocked with 2%BSA in PBS for 30
min. Cells were stained with primary antibodies for 1
hour. After washing, cells were incubated with corre-
sponding Alexa Fluor 488/594-conjugated secondary
antibodies for 1 hour. Stained cells were mounted with
SlowFade gold antifade reagent with DAPI, sealed with
nail polish, and observed with a confocal laser scanning
microscope (Radiance 2100, Bio-Rad Laboratories, Her-
cules, NJ). Negative controls were obtained by substitut-
ing the primary antibodies with corresponding
immunoglobulin isotypes.
Evaluation of cell viability
MTT reduction assay
Cell viability was determined by 3-(4, 5-Dimethyl-2-thi-
azolyl)-2, 5-diphenyl tetrazolium bromide (MTT) assay
(ATCC, Manassas, V A). Cortical cells were seeded with
density of 2 × 104 in a 96-well plate then cultured for 12
days. 10 μL of MTT stock solution (10 mg/ml) was added
to the hypoxic cells and incubated 2 hrs at 37°C. The
resulting MTT formazan was extracted with 100 μL of
detergent. The reaction product was analyzed at 570 nm
with a microplate spectrophotometer (Spectra max plus,
Molecular Devices, CA).
TUNEL assay
Apoptotic cells were determined by terminal deoxynucle-
otidyl transferase dUTP nick-end labeling (TUNEL)
assay. TUNEL staining was performed according to the
manufacturer's protocol. Cells were fixed with 4% para-
formaldehyde. Apoptotic cells were identified by strepta-
vidin-fluorescein detection of biotinylated dUTP
incorporation (TUNEL assay, R & D Systems, Minneapo-
lis, MN). Stained slides were visualized by confocal laser
scanning microscopy. Positive cells were counted and
considered as apoptotic cells.
Evaluation of cellular function
Electrophysiological recordings
Whole-cell recordings were made from 14-18 days cul-
tured cortical neurons at room temperature. Cover slips
containing cells were transferred to a small stage
mounted on an inverted microscope (Diaphot, Nikon)
and were superfused with extracellular saline solution
(ACF) containing (in mM): 137 Na-Isethionic acid, 4 K-
gluconate, 1.8 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose (pH
7.4 with NaOH). Recording electrode pipettes had resis-
tances of 2-4 MΩ and were filled with an internal pipette
solution containing (in mM): 130 K-gluconate, 1 MgCl2, 5
EGTA, 5 MgATP, 10 HEPES and 0.4 Na2GTP (pH 7.2
with KOH). Action potentials were evoked by injecting
depolarization current into primary cortical neurons
under normal conditions and recovery after treatment
with 1.5 mM NaCN for 30 mins.
Recordings were not performed during NaCN treat-
ment because the Ag-AgCl reference electrode can be
oxidized by NaCN which causes a pseudo neuronal mem-
brane depolarization artifact. Data were collected via a
patch clamp amplifier (Axopatch 200B), stored on a PC,
and analyzed by pClamp 9.0 software (Molecular
Devices, Sunnyvale, California). After whole-cell configu-
ration was achieved, series resistance was compensated
by 80~90% and monitored periodically. Most cultured
cortical neurons had series resistance around 7-8 MΩ
(range, 4-13 MΩ). A small percentage of cortical neurons
were considered as unhealthy and discarded due to rest-
ing membrane potentials less than -55 mV or gradual
changes in membrane potential, input resistance, or
action potential amplitudes. For current-clamp record-
ings, a depolarizing current step was injected to induce
multiple action potentials. To quantitatively measure the
changes in cultured neuronal network activities, the
duration of plateau depolarization was monitored in
batches of three minute recordings.
Dendrite spine count
Cortical cells were seeded on a poly-D-lysine coated
cover slip in 25 mm diameter at a density of 3 × 105 in 6-
well plate. Cultured cortical cells were transfected with 2
μg of green fluorescent protein (GFP) plasmid mixed with
0.5 M CaCl2 and HEBS solution for 40 min, washed with
DMEM, then normal neurobasal medium was added.
Two weeks following GFP transfection, cultured cells
were placed on a microscope stage incubation chamber
with 37°C and 5% CO2 control (Wellcome Trust Center
for Human Genetics, UK) then filled with ACF buffer 2
hours before image capture. Images were acquired by
using an inverted Zeiss LSM 510 META confocal micro-
scope with a 40× oil immersion objective and a digital
zoom of 3×. Image stack was generated by reconstructing
8 sections at an interval 0.4 μm from each slide. The mea-
surements of spine density were determined by counting
spines from the length of a 20 μm secondary dendrite
from each individual neuron. The rate of N/N0 was used
in the statistics. N corresponds to the total number of
dendritic spines at each time point and N0 indicates the
number before NaCN administration.
Statistics
Statistic analysis was performed using commercially
available software (GraphPad InStat). Differences among
the groups were determined by one-way ANOVA fol-Wang et al. Journal of Neuroinflammation 2010, 7:24
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lowed by Newman-Keuls test. Data are expressed as
mean ± S.E.M. and p value < 0.05 was considered signifi-
cant.
Results
DAF reverses the reduction of plateau depolarization 
inhypoxic neurons
To determine the dosage, immunoblotting and confocal
microscopic analysis were used to examine the genera-
tion of C3a in hypoxic rat primary cortical neurons. DAF
displayed a biphasic effect on C3a generation triggered
during the exposure of cells to the hypoxic insult (Fig. 1).
Within the 50 to 200 ng/ml range, recombinant human
DAF was able to suppress C3a production in a dose-
dependent manner. Significant inhibition of C3a was
apparent in the presence of 50 ng/ml of DAF and reached
a maximal level at 200 ng/ml. Interestingly, higher doses
of DAF (400 ng/ml) did not show complement inhibition.
Accordingly, 200 ng/ml of DAF was chosen to evaluate
the function of DAF in suppressing complement activa-
tion and neuroprotection.
To establish whether DAF displays beneficial effects on
neuronal excitability and activity under NaCN induced
hypoxia, whole-cell patch-clamp recordings from rat pri-
mary cortical neurons were performed. Action potentials
were elicited in whole cell current-clamp recordings.
Neuronal action potential discharges were observed in all
four groups. No significant difference in repetitive firing
evoked by long depolarization pulse (130 pA, 1 second)
(Fig. 2a) and spike frequencies induced by injecting dif-
ferent depolarization currents (Fig. 2b) was observed
among the groups. Spontaneous plateau depolarization
potentials were recorded after 14 days in culture. The pla-
teau potentials with burst firing were inhibited by excit-
atory glutamatergic blockers of AMPA and NMDA
receptors, CNQX (50 μM) and D-AP5 (50 μM) (Fig. 2c).
Spontaneous plateau potential with burst firing was used
as an index to reflect neural network activity. Spontane-
ous plateau depolarization potentials were significantly
reduced in hypoxic cells (Fig. 2d). However, treatment
with DAF profoundly reversed the reduction in plateau
depolarization potentials induced by NaCN (Fig. 2d). Fig-
ure 2e shows that the duration of plateau potential with
burst firing was considerably shorter in hypoxic neurons
compared to controls whereas DAF appears to have cor-
rected the neural change induced by NaCN. This obser-
vation suggests that DAF protects neuronal network
activity from adverse effects generated by chemical isch-
emia.
DAF prevents dendritic spine loss induced by hypoxia
Dendritic spine structures and dynamics are important
predictors of the function of neural networks [20]. To
investigate the potential effect of DAF on morphological
changes of neuronal dendritic spines caused by ischemia-
like conditions, GFP-transfected neurons were subjected
to NaCN and subsequently imaged. The number of den-
dritic spines in each group was counted. Spine density
measurements were determined by counting spines in the
length of a 20 μm secondary dendrite from each individ-
ual neuron. The rate of N/N0 was used, N corresponding
to the total number of dendritic spines at each time point
and N0 indicating the number before NaCN administra-
tion. Figure 3a shows time lapse recordings which reveal
that NaCN induced morphological alterations which
became more pronounced over time. Figures 3a and 3b
show that treatment with DAF resulted in significant pro-
tection against neuronal dendritic spine loss.
DAF increases viability and decreases apoptosis of cultured 
hypoxic neurons
To study whether DAF protects neurons from damage
induced by ischemic conditions, primary cortical neuron
cultures were exposed to glucose-free medium that con-
tained 1.5 mM NaCN. Cyanide selectively produces
either apoptosis or necrosis depending on cell type and
cyanide concentration [17,21]. Cell viability and apopto-
sis were assessed by MTT cell proliferation and TUNEL
apoptosis assays respectively. MTT demonstrated that
exposure of neuronal cultures to NaCN led to 41% more
damaged neurons when compared to controls (the con-
trol set as 100%) (Fig. 4c). DAF added to the culture
medium one hour after the induction of chemical
hypoxic ischemia significantly increased cell survival by
Figure 1 Recombinant human DAF dose response to C3a genera-
tion in cultured primary neurons. Primary rat cortical neurons were 
exposed to glucose free medium containing 1.5 mM NaCN for 1 hr, 
then recovered in normal medium for 4 hrs with 0, 50, 200, 400 (ng/mL) 
of recombinant human DAF respectively. (a) Cell lysate was immunob-
lotted with anti c3a and anti β-actin antibodies (n = 5). (b) Data were 
quantified by densitometry. (one-way ANOVA followed by Newman-
Keuls test. * p value < 0.05, **p < 0.01).
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19% (Fig. 4c). TUNEL assay was used to determine
whether apoptosis occurred after NaCN induced isch-
emia. Figure 4a demonstrates that DAF reduced ischemic
induced apoptosis (DAPI localizes the nucleus, TUNEL
shows DNA fragmentation, and NF200 is a neuronal
marker). Figure 4b shows that ischemic conditions
increased positively labeled neuronal nuclei by 60% when
compared to cells from control or DAF groups. This data
indicates that this hypoxic-ischemic model mainly trig-
gers neuronal apoptosis, not necrosis. However, the pres-
e n c e  o f  D A F  p o s t  N a C N  i n s u l t  r e s u l t e d  i n  a  d e c r e a s e
(23%) in the number of TUNEL labeled nuclei. Therefore
the beneficial effects associated with DAF on cell viability
in this model may be attributed, at least in part, to its abil-
ity to inhibit neuronal apoptosis.
DAF suppresses NaCN-induced C3 protein expression
To detect whether neurons constitutively produce C3,
immunofluorescent staining with anti-C3 antibody and
neuronal marker anti-NF-200 was performed. Cultured
rat neurons intrinsically express C3 protein which is
accumulated primarily at the membrane and cytoplasm
of the neuronal body (Fig. 5). C3 is increased after chemi-
cal hypoxic exposure, however DAF treatment signifi-
cantly attenuated this protein expression.
DAF decreases C3a and C3aR production, C3a-C3aR 
engagement, and MAC formation under hypoxic-ischemic 
conditions
To determine whether DAF interferes with complement
activation as it relates to neuronal cells, immunoblotting
and confocal microscopic analysis were used to examine
the generation of C3a in hypoxic rat primary cortical neu-
rons. Cleavage of the C3 component releases the small
peptide anaphylatoxin C3a. Interestingly, soluble C3a (9
kD) was significantly elevated in neurons subjected to
hypoxic-ischemic conditions whereas C3a was dramati-
cally inhibited in the presence of DAF (Fig. 6a). To
Figure 2 Effect of DAF and NaCN on neuronal excitability and plateau depolarization in cortical neurons. Rat primary cortical neurons were 
cultured for 14-18 days before electrophysiological recording. (a) Effect of DAF and NaCN on action potential discharge in cortical neurons. Repetitive 
firing was evoked by long depolarization pulse (130 pA, 1 second). (b) Spike frequencies induced by injecting different depolarization currents. Spike 
frequency is defined as the number of spikes per sec. (c) Neural network activity reflected by plateau depolarization. The representative traces show 
AMPA- and NMDA-mediated spontaneous plateau potential and burst firing. Insert shows spontaneous plateau potential and burst firing at a much 
higher time resolution. (d) Effects of DAF and NaCN on plateau depolarization. The typical recordings showing NaCN induced a remarkable reduction 
in spontaneous plateau potential and burst firing. (e) The spontaneous plateau depolarization was monitored over a three minute period. The data is 
presented as mean ± SEM. The number of cells recorded is indicated in parentheses and columns (b and e). (one-way ANOVA followed by Newman-
Keuls test. *p < 0.05 and **p < 0.01).
200 ms
40 mV
130 pA
-63 mV
-63 mV
-63 mV
-63 mV
Control
NaCN
DAF
NaCN+DAF
a
0
5
10
15
20
25
30
35
40
10 40 70 100 130 160 190
ControL(8)
DAF(7)
NaCN(14)
NaCN+DAF(12)
S
p
i
k
e
 
F
r
e
q
u
e
n
c
y
 
(
H
z
)
Injection Currents (pA)
b
20 mV
40 ms
40 mV
30 s
-64 mV
-64 mV
-63 mV
-66 mV
Control
DAF
NaCN
NaCN+DAF
d
0
5
10
15
20
25
**
*
P
l
a
t
e
a
u
 
d
e
p
o
l
a
r
i
z
a
t
i
o
n
 
(
s
/
1
8
0
s
)
 
e
8        7 
14 12Wang et al. Journal of Neuroinflammation 2010, 7:24
http://www.jneuroinflammation.com/content/7/1/24
Page 6 of 13
address how soluble C3a associates with neurons, immu-
nofluorescent staining using anti-C3a and anti-C3aR
antibodies conjugated with Alexa Fluor 488/594 was con-
ducted. Under hypoxic-ischemic conditions, rat neurons
demonstrated a significant increase in C3a generation
accompanied by stronger C3aR staining which was
observed primarily at the membrane and cytoplasm of
the cell body, where colocalization was quite apparent.
Treatment with DAF resulted in a reduction of C3a and
C3aR expression as well as reduced C3a and C3aR colo-
calization (Fig. 6b). Cultured neurons exposed to isch-
emia-like conditions resulted in enhanced MAC
accumulation, primarily on the cell membrane (Fig. 6c).
In contrast, DAF treatment reduced MAC distribution in
response to the insult (Fig. 6c). DAF decreases C3a gener-
ation and MAC formation in cultured neurons under
hypoxic-ischemic conditions.
DAF inhibits caspase-3 activation in hypoxic neuronal cells
To examine the effect of DAF on caspase enzymes, acti-
vated caspase-3 and caspase-9 expression were moni-
tored by immunoblotting. Hypoxic neurons exhibited
strikingly increased expression of active caspase-3 and
caspase-9 when compared to neurons cultured in normal
medium (Fig. 7a and 7b). However, neurons treated with
DAF significantly downregulated hypoxia-induced acti-
vation of caspase signaling. This data suggests a novel
molecular role for DAF in neuroprotection which
involves the suppression of caspases. Additionally,
hypoxic neurons displayed strong active caspase-3 stain-
ing distributed within the neuronal apoptotic bodies,
around fragmented/cleaved nuclei, and at the cytoplas-
matic membrane blebbing where they exhibited colocal-
ization with MAC (Fig. 7c and 7d). Conversely,
expression of active caspase-3 and colocalization of active
caspase-3 and MAC in the plasma membrane blebbing
were significantly reduced in cells treated with DAF (Fig.
7c and 7d). These observations imply a potential role of
DAF in disrupting the interaction between caspase-3 and
MAC in neurons undergoing hypoxia.
DAF suppresses c-Src activation in hypoxic neurons
c-Src is extensively expressed in brain cells [22] and is
present at much higher levels in neurons than in other
brain cells which suggests that it is important to neuronal
function. Activated Src plays a pivotal role in neuronal
ischemia/reperfusion-mediated injury [23,24]. To further
understand the neuroprotective role of DAF in neurons
under chemically induced hypoxic conditions, activated
c-Src was determined by western blotting using an anti-
activated Src antibody. Figure 8 shows that hypoxic neu-
rons displayed higher levels of activated c-Src compared
to control neurons. However, DAF suppressed the quan-
tity of activated c-Src induced by the ischemic insult (Fig.
8). These findings imply that DAF-mediated neuropro-
tection involves inhibition of c-Src activation in neurons
exposed to chemical hypoxia.
Recombinant human DAF can anchor to rat neurons
To find out whether recombinant human DAF is able to
bind to rat neurons, recombinant human DAF incorpora-
tion in cultured rat neurons was determined by
immunestaining using anti-human DAF antibody. As
shown in Fig. 9, both DAF-treated groups had an obvious
recombinant human DAF-stained signal. This staining
signal was not observed in control or NaCN groups.
Endogenous rat DAF (rDAF) in neurons was also ana-
lyzed using immunofluorescent staining. The cultured
normal neurons constitutively produced rDAF, but at a
very low amount particularly when compared to the level
of exogenous anchored recombinant human DAF in DAF
treated groups (Fig. 9). This observation is consistent
Figure 3 Time-lapse imaging reveals DAF reduces NaCN-induced 
dendritic spine loss. Primary cortical neurons were in ACF buffer with 
5% CO2 at 37°C for 2 hours before experiment. (a) GFP positive neuron 
images represent several time points during exposure to 1.5 mM NaCN 
with and without DAF. Arrow shows spine loss. (b) Images were ana-
lyzed by counting dendritic spines prior to and 1 hour after NaCN treat-
ment. Scale bar = 2 μm. (one-way ANOVA followed by Newman-Keuls 
test. *p < 0.05, **p < 0.01).
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with previous reports [10] suggesting that neurons are
susceptible to complement-mediated cellular damage.
A l t h o u g h  i t  i s  n o t e w o r t h y  t h a t  c o m p l e m e n t  a c t i v a t i o n
existed (Fig. 6) the overall levels of endogenous rDAF
were not significantly altered following chemical hypoxic
exposure (Fig. 9). This indicates that a supply of exoge-
nous DAF would be necessary to protect neurons from
hypoxic-ischemia insults.
Discussion
Two major questions have been addressed in this study.
First, does the presence of soluble DAF attenuate neu-
ronal damage induced by the chemical hypoxic condi-
tions? Second, how does DAF protect neurons from the
hypoxia-mediated injury? The results demonstrate that
treatment with DAF protects cellular function and
increases cell viability in a cultured neuronal chemical
hypoxia model. DAF decreases complement activation
and distribution. Furthermore, this protective effect of
DAF is associated with the ability to directly inhibit com-
plement activation and suppress (directly or indirectly)
Src tyrosine kinase and caspase signaling pathways.
Cyanide is a toxic chemical that has been used as a
weapon of war and also as means of terrorist attacks on
civilian populations [25]. It inhibits the respiratory chain,
blocking the utilization of oxygen and affecting mito-
chondrial function [17]. Neurons are particularly vulner-
able to energy deprivation [26]. Therefore, one of the
main target organ system of cyanide toxicity is the central
nervous system. NaCN treatment, which mimics acute
hypoxic cell damage, is commonly used as an experimen-
tal model to study hypoxia in vitro [17]. This model is
generally used to measure neuronal viability [27] and pro-
vides a means to measure metabolic stress and mitochon-
drial dysfunction as it relates to excitability of neurons
[26]. In addition, NaCN has been used to elucidate mech-
anisms of ischemic preconditioning [28] and screen for
potential neuroprotective compounds/drugs [29]. Here
Figure 4 DAF reduces neuronal cell death induced by ischemia. Primary rat cortical neurons were exposed to glucose free medium containing 
1.5 mM NaCN for 1 hr, then recovered in normal medium with and without DAF for 24 hours. (a) The effects of DAF on the apoptosis of primary cul-
tured neuronal cells as measured by TUNEL assay. DAPI localizes the nucleus (blue), TUNEL shows DNA fragmentation (green), and NF200 shows neu-
rons (red). Positive cells were counted and considered as apoptotic cells (n = 5). Scale bar = 20 μm. (b) The apoptotic cells were counted as described 
in the methods and the cumulative data from five independent experiments was shown here. (c) The neuronal viability determined by MTT assay (n 
= 5). (one-way ANOVA followed by Newman-Keuls test. * p < 0.05 and **p < 0.01).
a
NaCN+DAF
TUNEL DAPI
Control
DAF        
NaCN
Merge NF200
(n=5)
c
**        *
0
20
40
60
80
100
%
 
R
a
t
i
o
 
o
f
 
V
i
a
b
i
l
i
t
y
b
0
20
40
60
80
100
%
 
o
f
 
A
p
o
p
t
o
t
i
c
 
n
u
c
l
e
i
**         *
Control DAF NaCN NaCN+DAF
Figure 5 Treatment with DAF suppresses NaCN induced expres-
sion of C3 protein in neurons. Primary neurons in glucose-free medi-
um were exposed to 1.5 mM of NaCN for 1 hour then the cells were 
bathed in normal medium with or without 200 ng/ml of DAF. Expres-
sion and distribution of C3 in the neurons was assessed by immunoflu-
orescent staining using anti-C3 (green), anti-NF200 (red), and DAPI 
(blue) antibodies (n = 3). Original magnification: ×400. Scale bar = 50 
μm.
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we used NaCN combined with glucose deprivation to
mimic a hypoxic ischemic environment in order to inves-
tigate the effects of DAF on neuronal injury and to
explore the potential mechanisms of DAF associated with
neuroprotection.
Electrophysiological changes caused by hypoxic-isch-
emic conditions are an early sign of neuronal injury and
indicator of the degree of injury [30]. Data recorded dur-
ing cell recovery in normal medium showed that neither
NaCN nor DAF changed cortical cell excitability in our
model. Spontaneous neuronal electrical activity is critical
for many aspects of developmental processes at all stages,
such as central axon growth, navigation, and pruning of
inappropriate connections [31]. We used glutamatergic
AMPA- and NMDA-mediated spontaneous plateau
depolarization potentials and burst firing as an index to
study neural network activities. The addition of NaCN
significantly reduced neuronal spontaneous plateau
potential and burst firing whereas DAF reversed these
effects. This finding demonstrates that DAF promotes
recovery of neuronal network dysfunction induced by
hypoxia.
Dendritic spines are micron-sized protrusions of the
dendritic membrane that serve as the postsynaptic com-
ponent for the vast majority of central nervous system
excitatory and inhibitory synapses. Spines play a crucial
c i r c u i t  r o l e  t o  s y n a p t i c  m a t r i x  e l e m e n t s  o f  a s s o c i a t i v e
neural networks and changes in dendritic spine length or
shape have been shown to significantly alter the func-
tional properties of neurons [32]. Dendrite spines can be
induced rapidly [33] or reduced and structurally changed
due to severe ischemia (within 10 min) and can be
observed in the peri-infarct cortex after focal stroke in
vivo [34]. In this study, shrinkage of dendritic spines post
NaCN administration was apparent as early as 10 min
and significant loss of spines was evident at 60 min.
Figure 6 DAF reduces interaction of C3a-C3aR and MAC formation in rat neurons subjected to hypoxic-ischemic conditions. Primary rat cor-
tical neurons were exposed to NaCN for 1 hr then allowed to recover for 24 hours in normal medium with or without DAF. (a) Cell lysates were analyzed 
by immunoblot using anti-C3a and anti-β-actin antibodies. Data was quantified by densitometry (n = 5). (b) Interaction between neuronal C3a and 
C3aR was determined by immunofluorescent staining using anti-C3a (red) and anti-C3aR (green) antibodies (n = 3). Enlarged images are in the lower 
left boxes of merged images. (c) Cells were stained with mouse anti-rat MAC antibody (green), DAF resulted in a decrease in MAC formation (n = 3). 
Original magnification: ×400. Scale bar = 50 μm. (one-way ANOVA followed by Newman-Keuls test. *p value < 0.05, **p < 0.01).Wang et al. Journal of Neuroinflammation 2010, 7:24
http://www.jneuroinflammation.com/content/7/1/24
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Treatment with DAF resulted in a significant reduction of
dendritic spine loss. These results suggest that DAF plays
a role in preserving synaptic morphology during hypoxia.
It has long been believed that severe or prolonged isch-
emia/hypoxia leads to neuronal cell apoptosis. Consistent
with previous findings [35], when our cultured rat corti-
cal primary neurons were exposed to chemical hypoxia,
cell apoptosis was significantly increased. Indirect evi-
dence for the participation of DAF in apoptotic events
has been demonstrated in malignant tumors [36] and
neutrophils [37]. In this study, DAF-treated cells showed
an attenuated level of neuronal cell apoptosis induced by
the hypoxic-ischemic insult.
We observed that cultured rat neurons constitutively
possessed C3 protein which is consistent with recent
findings demonstrating that C3 was present in mouse
neurons [4].
In previous studies from our laboratory, DAF was
shown to inhibit formation of MAC in murine mesenteric
I/R models [[16] and unpublished data] as well as sup-
press production of C3a and MAC in rodent and porcine
hemorrhagic shock [unpublished data]. Of particular
interest is our observation that treatment with DAF sig-
Figure 7 DAF suppresses the expression of activated caspase in neurons exposed to chemical hypoxia. Primary rat cortical neurons were ex-
posed to glucose free medium containing 1.5 mM NaCN for 1 hr then allowed to recover overnight in normal medium with or without DAF. (a) Cell 
lysates were analyzed by immunoblot using anti-active caspase-3, anti-caspase-9, and anti-β-actin antibodies. (b) Data was quantified by densitometry 
(n = 10). (c and d) Cells were marked with anti-active caspase-3 (red), anti-MAC (green) antibodies, and DAPI (blue) (n = 3). Scale bar = 50 μm. (one-
way ANOVA followed by Newman-Keuls test. *p < 0.05).
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nificantly reduced the increase in C3 expression as well as
C3a and MAC formation in hypoxic neuronal cells.
In addition to the well-described regulatory function of
DAF on complement activation [13], it has become
increasingly apparent that this molecule might also act as
a signal-transducing molecule. DAF has been found to
associate with Src protein tyrosine kinases such as p56lck
and p59fyn in human T cells [38]. There is strong evi-
dence demonstrating that cerebral ischemia/reperfusion
induces Src activation in rat hippocampus [39]. Further-
more, blockade or deficiency of Src activity minimized
brain injury following stroke in mice [23]. Src family
kinase inhibitors PP1 and PP2 decreased brain injury
induced by intracerebral hemorrhage, ischemia/reperfu-
sion and neurosurgical procedure [23,40]. In the present
study, we demonstrate that DAF treatment significantly
decreases the activation of c-Src during ischemia-like
conditions. Although the mechanism by which DAF reg-
ulates activation of Src kinase is unknown, there is
increasing evidence that Src family kinases act as a point
of convergence for various signaling pathway, including
the pathway that signals via G-coupled receptors [41].
Thus, it is possible that the inhibition of c-Src activity by
DAF could be via a direct association of DAF and c-Src.
Neurons have been identified as the principal CNS cell
that prominently expresses the C3a receptor under physi-
ological conditions [4]. Significant up-regulation of C3aR
in murine brain after cerebral ischemia has been
observed [42]. We found that DAF dramatically dimin-
ished neuronal C3aR induced by the hypoxic-ischemic
conditions. C3aR specifically binds with high-affinity to
C3a and high-affinity binding sites are abundantly
expressed (20,000 to 80,000 sites per cell) on cultured
human astrocytes [43]. The finding that increased C3aR
was present in hypoxic cultured neurons and was associ-
ated with C3a is quite important since this can explain
why soluble C3a was detected in the cell lysates. C3a-
C3aR interaction was markedly reduced in the presence
of DAF by limiting expression of C3aR and C3a. C3aR is a
G protein-coupled receptor which initiates intracellular
signaling when C3a binds to it [44,45]. Our findings sug-
gest that autocrine/intracrine C3a might be involved in
the regulation of neuronal functions via binding to C3aR
and subsequent C3a-C3aR engagement which implies a
key link to the down-stream Src and caspase signals.
Sublytic MAC may initiate cellular signal transduction
pathways resulting in activation of cell survival mecha-
nisms [46]. However, clinical and experimental studies
have implied a pivotal role for MAC in the pathogenesis
of secondary neuronal cell death after TBI [47,48]. In our
study, an increase in MAC was associated with neuronal
injury suggesting lytic formation of this complex due to
hypoxia is associated with cytotoxicity and subsequent
cell death in this model. Taken together these observa-
tions suggest that the protective effects of DAF are
related to attenuation of C3a-C3aR-Src/caspase and/or
MAC-Src signaling pathways. However, this assumption
is speculative and needs further investigation.
The central components of the apoptotic processes are
the caspases. Cross-linking of DAF isoform with its anti-
body in human stomach adenocarcinoma cells elevated
the expression of caspase-3 and caspase-8, and activated
Figure 8 DAF down-regulates the expression of activated Src in 
cultured primary neurons exposed to NaCN. Cells were exposed to 
glucose free medium containing 1.5 mM for 1 hr then recovered in 
normal medium for 24 hrs with/without 200 ng/mL of DAF. Protein ex-
tractions were immunoblotted with anti-activated Src and anti-β-actin. 
(b) Data was quantified by densitometry (n = 10). (one-way ANOVA fol-
lowed by Newman-Keuls test. **p < 0.01, *p < 0.05).
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caspase-3 [49]. But in hypoxic cultured neurons, we
observed that application of DAF down-regulated the
expression of caspase-9 and reduced caspase-3 activity.
Lytic levels of MAC can trigger caspase signal pathway
resulting in cell lysis or apoptosis [50,51] therefore it is
very likely that in this model, DAF functions by downreg-
ulating caspase at least in part by blocking MAC forma-
tion. Indeed, we found that treatment with DAF
diminished the colocalization/interaction of active cas-
pase-3 and MAC caused by hypoxic conditions. This
finding suggests that in addition to suppressing comple-
ment activation and Src kinase activity, DAF exerts its
neuronal protective effect against hypoxia through a
direct or indirect blockage of the caspase pathway.
The present study utilized cultured chemically hypoxic
primary cortical neurons as a model of neuronal injury.
Extrapolation of our findings to support pharmacothera-
peutic innovation for the treatment of ischemic brain dis-
eases should be weighed carefully. First, the model does
not account for the role of other cellular components
known to play a role in cerebral damage after ischemia
and/or hypoxia. Astrocytes, oligodendrocytes and micro-
glial cells have been reported to provide major sources of
local complement activation during brain injury [4,8].
Second, studies on Src family kinase signaling in models
of cerebral ischemia have revealed that ischemia induces
an increase in tyrosine phosphorylation of n-methyl-d-
aspartate (NMDA) receptors (NMDAR) by Src family
kinases [52,53] suggesting that enhancement of Ca2+
entry induced by the phosphorylated NMDARs or other
proteins in the NMDAR complex may be important dur-
ing activation of intracellular signaling cascades leading
to cell death. Our study suggests that DAF interferes with
complement activation, but it does not exclude the
involvement of other DAF functions such as direct regu-
lation of mitochondrial factors (e.g. apoptosis inducing
factors), calcium signaling, NMDAR signaling, or actin
cytoskeleton. Future studies will be necessary to deter-
mine whether DAF exerts a direct effect beyond comple-
ment inhibition on c-Src, NMDARs, transcription factors
and caspases, and if so, to what extent these direct inter-
actions contribute to the protective effects of DAF
against neuronal damage during ischemia-like condi-
tions.
Conclusion
Our data indicate that neuronal injury induced by chemi-
cal hypoxic insult can be prevented by DAF at the level of
neuronal network, dendritic spine morphology, and neu-
ronal apoptosis. Moreover, in addition to complement
and caspase pathways, our data also suggests that DAF
exhibits neuroprotection through down regulation of Src
activity.
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